Discussion
Breast cancer is the most frequently diagnosed malignancy in women. Heterogeneous distribution of hypoxic regions is commonly detected within invasive breast tumors [
14,
26]. These resistant regions are known to have larger tumor sizes, and to consist of worse grade tumors that are invasive and metastatic [
25]. The use of hypoxia-activated drugs is among the leading approaches to circumvent hypoxia challenges [
16]. This strategy provides selective tumor suppression, thus offering minimal toxicity to non-hypoxic tissues. Several hypoxia-activated compounds have reached clinical trials for the treatment of a variety of solid tumors [
30‐
36]. However, so far these drugs have shown moderate to low activity against breast cancer. Here, we document for the first time that DCQ is a hypoxia-activated cytotoxin effective against breast cancers that harbor different p53 status and have different invasive potential. We show that DCQ induces apoptosis and reduces HIF-1α regulated pathways. In human breast cancer xenograft model, DCQ attenuated metastasis to the lungs and liver and significantly reduced tumor growth as compared to control mice (DMSO-treated). Additionally, DCQ prolonged the survival of 50% of treated mice beyond 60 days, by that time, however, 90% of untreated mice have already died. These data suggest that targeting breast cancer with the hypoxia-activated drug DCQ is a potential therapeutic approach to suppress metastasis through the reduction of HIF-1α and downstream activated pathways.
It has been shown that DCQ exerts its cytotoxic activity through different cellular mechanisms in a cell-type specific manner [
18‐
22]. In this study, DCQ was found to reduce the viability and colony forming ability of MCF-7 and MDA-MB-231
via the induction of apoptosis, an effect that was significantly enhanced under hypoxia. Interestingly, the p53 mutant and invasive MDA-MB-231 cell line was more sensitive to DCQ than p53 wild type MCF-7 cells. In order to rule out the possible involvement of p53 in drug sensitivity, we silenced functional p53 in MCF-7 cells, and found that DCQ-induced apoptosis was not enhanced, suggesting that the higher drug sensitivity in MDA-MB-231, which provides additional selectivity for tumor versus normal tissue toxicity, may not be attributed to p53 status. This extends previous observations that DCQ-induced apoptosis in HCT116 human colon cancer cells is independent of p53 [
19], rendering DCQ a promising molecule, especially when considering that more than 50% of human cancers bear mutated or abnormal p53.
Most hypoxia-activated drugs undergo bio-reductive activation, which generates intra cellular reactive radicals, namely hydroxyl radicals that break cellular DNA ultimately leading to apoptosis [
16,
17]. Using alkaline comet assay, we have previously demonstrated that DCQ, when combined with radiotherapy, induces DNA damage [
19,
22,
24]. In accordance with these findings, DCQ increased the levels of the DNA damage marker gamma-H2AX in both breast cancer cell lines. Together with previous findings [
24], these data provide evidence that DCQ is a potent DNA damaging agent under hypoxic conditions.
ROS are known to mediate the DNA damaging effects of hypoxia-activated prodrugs [
17]. In our breast cancer system, DCQ significantly increased the levels of intracellular ROS under hypoxia after 1 hour of exposure. Interestingly, a more pronounced increase of ROS generation was observed in MDA-MB-231 (90%) than MCF-7 cells (60%), which could explain the higher sensitivity of MDA-MB-231 cells to DCQ. In fact, it has been documented that MCF-7 cells are resistant to ROS-dependent apoptosis due to the high basal levels of NRF2, a transcription factor involved in protective responses to oxidants, as well as to elevated levels of intracellular glutathione [
36]. In both breast cancer cell lines, DCQ-mediated cell death appears to require ROS production since drug toxicity was reversed by the antioxidants vitamin E and DTT.
Almost 50% of breast cancer patients treated for localized disease develop metastases [
25]. Evidence suggests that hypoxia contributes positively to breast tumor invasion and metastasis [
25,
26]. Recent studies show that hypoxia aids in the development or maintenance of breast cancer stem cells [
37,
38]. HIF-1α is a major molecular player by which hypoxia orchestrates such complex patterns of gene expression in most solid tumors including breast cancer [
39‐
41]. Among other hypoxia-activated prodrugs, DCQ-induced cell death was accompanied by a reduction in the levels of HIF-1α in many cell lines [
18‐
22]. In MDA-MB-231 cells, DCQ reduces both basal and hypoxia-induced accumulation of HIF-1α
via proteasomal degradation. In MCF-7 cells, it has been reported that the activation of p53, by DNA damaging agents, targets HIF-1α to proteasome-dependent degradation [
28]. Here we show that DCQ induces DNA damage in MCF-7 cells, however, unlike other DNA damaging agents, it does not induce a proteasome-dependent degradation of HIF-1α. Moreover, silencing p53 led to a non-significant reversal of DCQ-induced down regulation of HIF-1α. These data provide evidence that DCQ does not target HIF-1α to degradation. Since, treating MCF-7 cells with DCQ did not affect the mRNA transcript levels of HIF-1α (data not shown), we suspected a possible anti-translational activity of DCQ. One of the major oncogenic pathways that shift the balance towards HIF-1α accumulation,
via increased translation, is the AKT/mTOR pathway [
8,
42‐
44]. In fact, Zhan et al. reported that in Hela cells, TPZ suppresses the translation of HIF-1α in an eIF2α dependent manner [
29]. This suppression was accompanied by an increase in the levels of p-AKT (Ser 473) and a reduction of p-mTOR (Ser 2448) [
29]. Similar to TPZ, DCQ induced an increase in the levels of p-AKT (Ser 473) and a reduction of p-mTOR (Ser 2448), suggesting a possible anti-translational activity in MCF-7 cells. Taken together, we show that DCQ reduces HIF-1α in MDA-MB-231 and MCF-7 cells
via distinct mechanisms and possibly independently of its DNA damaging effect (Additional file
1: Figure S5).
HIF-1α is known to activate vital pathways involved in metastasis [
8]. In our breast cancer system, DCQ not only reduced HIF-1α but also attenuated hypoxia-induced invasion. The reversal of hypoxia induced VEGF secretion is in accordance with the anti-angiogenic effect of DCQ documented earlier in mouse mammary epithelial cells in C57BL mice [
23]. HIF-1α plays a central role in metastasis
via direct regulation of several EMT regulators such as Snail, SLUG, and TWIST [
11‐
14]. Here we report that targeting breast cancer cells with the hypoxia-activated drug, DCQ, reduces hypoxia-induced EMT, as indicated by the reduction of hypoxia-induced cell migration in MCF-7 cells and downregulation of TWIST in MDA-MB-231. In MDA-MB-231, the incomplete abrogation of HIF-1α and TWIST possibly explains the limited effect of DCQ on hypoxia-induced migration in this cell line [
12]. In fact, exposure of MDA-MB-231 to hypoxia did not significantly alter their behavior, which may be due to the considerably high basal levels of HIF-1α in this cell line or to the constitutive activation of several oncogenic pathways involved in angiogenesis and EMT in these cells [
12,
13,
25,
45].
The present study shows that the hypoxia-activated drug, DCQ, is more effective than the clinically used drug tirapazamine (TPZ) against breast cancer cell lines. DCQ induces ROS-dependent, p53-independent apoptosis in breast cancer cell lines in vitro. Additionally, DCQ reduces primary tumor volume, reduces secondary site invasion, and significantly increases survival in vivo. DCQ exhibits its unique pro-apoptotic and anti-metastatic properties via the reduction of HIF-1α and downstream signaling cascades.